Cargando…

Translating KEYNOTE-048 into practice recommendations for head and neck cancer

Detalles Bibliográficos
Autores principales:	Szturz, Petr, Vermorken, Jan B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475419/ https://www.ncbi.nlm.nih.gov/pubmed/32953775 http://dx.doi.org/10.21037/atm.2020.03.164

Ejemplares similares

Editorial: Head and neck cancer in the elderly
por: Szturz, Petr, et al.
Publicado: (2023)

Immunotherapy in head and neck cancer: aiming at EXTREME precision
por: Szturz, Petr, et al.
Publicado: (2017)

Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice
por: Szturz, Petr, et al.
Publicado: (2019)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
por: Sano, Daisuke, et al.
Publicado: (2023)

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
por: Szturz, Petr, et al.
Publicado: (2016)

Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond
por: Szturz, Petr, et al.
Publicado: (2021)

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
por: Pai, Sara I., et al.
Publicado: (2019)

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
por: Harrington, Kevin J., et al.
Publicado: (2023)

Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity
por: Szturz, Petr, et al.
Publicado: (2020)

Estimating the Prevalence of a True Oligometastatic Disease
por: Szturz, Petr, et al.
Publicado: (2022)

Head and Neck Cancer
por: Psyrri, Amanda, et al.
Publicado: (2009)

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
por: Burtness, Barbara, et al.
Publicado: (2022)

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019)

Steering decision making by terminology: oligometastatic versus argometastatic
por: Szturz, Petr, et al.
Publicado: (2022)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Editorial: Insights in head and neck cancer: 2021
por: Lybaert, Willem, et al.
Publicado: (2023)

Oligometastatic Disease Management: Finding the Sweet Spot
por: Szturz, Petr, et al.
Publicado: (2020)

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study
por: Gómez-Randulfe, Igor, et al.
Publicado: (2023)

KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
por: Zaryouh, Hannah, et al.
Publicado: (2022)

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
por: Specenier, Pol, et al.
Publicado: (2012)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Is Quality of Life “The Heart of The Issue” In Head and Neck Cancers?
por: Laskar, Sarbani Ghosh, et al.
Publicado: (2014)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
por: Wang, Yanye, et al.
Publicado: (2020)

Editorial: Quality Assessment Across Disciplines in Head and Neck Cancer Treatment
por: Vermorken, Jan B., et al.
Publicado: (2021)

Head and neck oncology: The Indian scenario
por: Shah, Snehal Bhupesh, et al.
Publicado: (2016)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
por: Cristina, Valerie, et al.
Publicado: (2019)

FADD the bad in head and neck cancer
por: Dent, Paul
Publicado: (2013)

Keynotes
Publicado: (2023)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

P048 Abstract Withdrawn
Publicado: (2021)

Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012
por: Tahara, Makoto, et al.
Publicado: (2018)

Getting the basics right-staging in head and neck cancer
por: Patel, Nimesh Narendra, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_0jm1bh7t53vbarsod1jumjapnd